Back to search results

Brain Mapping for Youth OCD Treatment

This study aims to understand if brain scan results can help predict and track changes in obsessive-compulsive disorder (OCD) symptoms in young people aged 10 to 17. Participants will receive Exposure and Response Prevention (ERP) therapy, a type of cognitive behavioral therapy where you face OCD-related fears while resisting compulsions. Researchers will use functional MRI (magnetic resonance imaging) brain scans to see if individual brain connection patterns can predict how well ERP works over a 14-week period and during follow-up booster sessions. All participants will receive ERP therapy, and the study is currently unclear on its recruitment status.

Study design
This is an interventional study with a planned enrollment of 30 participants, all receiving Exposure and Response Prevention Therapy.
What's involved
You would complete repeated clinical assessments and research MRI sessions at scheduled times throughout the study, including during and after a 14-week course of ERP.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured from Baseline through the end-of-acute ERP assessment visit, targeted at Week 14, and includes planned monthly booster sessions and additional booster sessions if symptoms worsen.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07570108

Precision Brain Mapping to Predict and Track Response to Exposure and Response Prevention Therapy in Youth With Obsessive-Compulsive Disorder

Withdrawn
NAAges 10–17InterventionalTreatment
Weill Medical College of Cornell University
Updated 2026-08-05 on ClinicalTrials.gov
What's tested:Exposure and Response Prevention TherapyClinical AssessmentsResearch MRI Sessions

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Association Between CY-BOCS-II Total Score and Orbitofrontal Cortex-Ventral Striatum Resting-State Functional Connectivity During Acute ERP
Measured over Baseline through end-of-acute ERP assessment visit, targeted Week 14

Conditions

Obsessive-Compulsive Disorder

Explore related trials

Obsessive Compulsive Disorder

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Conor Liston, MD, PhD · PRINCIPAL_INVESTIGATOR · Weill Medical College of Cornell University

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 10 to 17 years at the time of initial consent. Participants who reach age 18 while enrolled may remain in the study after completing the adult re-consent process; no new participants age 18 years or older will be recruited.
DSM-5 diagnosis of obsessive-compulsive disorder, established through a clinical interview by a clinician.
Parent or guardian able to provide informed consent and participant able to provide assent.
Participant has sufficient English fluency to complete cognitive tasks and assessments. Parent or guardian English fluency is not required; interpreter support is available.

Exclusion

History or current evidence of a significant neurological disorder, including but not limited to seizure disorder, stroke, or traumatic brain injury with loss of consciousness.
Any standard MRI contraindication identified during initial screening or on the MRI safety checklist, including but not limited to ferromagnetic implants, certain medical devices or metal fragments, severe claustrophobia, or pregnancy.
Pregnancy at screening or pregnancy identified during study participation.
Active suicidal ideation.
Any psychiatric condition that, in the investigator's judgment, would interfere with study participation or data interpretation, including but not limited to psychotic disorders, bipolar disorders, severe neurodevelopmental disorders, intellectual disability, severe eating disorders, or recent significant substance use disorders within the past 6 months. Stable psychiatric comorbidities, including anxiety disorders, depressive disorders, ADHD, or tic disorders, are permitted if OCD remains the primary diagnosis.
Any medical, psychiatric, or situational factor judged by the investigator as likely to compromise participant safety, adherence, or data integrity.

What this trial measures

  • Association Between CY-BOCS-II Total Score and Orbitofrontal Cortex-Ventral Striatum Resting-State Functional Connectivity During Acute ERPBaseline through end-of-acute ERP assessment visit, targeted Week 14

    The primary outcome is the within-participant association between obsessive-compulsive disorder symptom severity and resting-state functional connectivity during the acute ERP phase. OCD symptom severity will be measured using the Children's Yale-Brown Obsessive Compulsive Scale, Second Edition total score. OFC-ventral striatum resting-state functional connectivity will be measured using Fisher z-transformed resting-state fMRI connectivity. The association will be estimated using visit-level linear mixed-effects models. CY-BOCS-II total scores range from 0 to 50, with higher scores indicating greater OCD symptom severity.